IMG 25191

Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter

  • Company reports strong financial results for 2022 with 27% revenue growth in 2022 and
    significantly increased margins
  • Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as
    well as strong market growth
  • Continued market share gains, strategic mid-term revenue growth at a CAGR of 30%
    and further improvement of operating margins targeted


If you are a healthcare professional (HCP), please log in to see specific information about our products.



* fields are required